miR-21 may acts as an oncomir by targeting RECK, a matrix metalloproteinase regulator, in prostate cancer by Reis, Sabrina Thalita dos et al.
  Universidade de São Paulo
 
2012
 
miR-21 may acts as an oncomir by targeting
RECK, a matrix metalloproteinase regulator, in
prostate cancer
 
 
BMC UROLOGY, LONDON, v. 12, MAY 29, 2012
http://www.producao.usp.br/handle/BDPI/35852
 
Downloaded from: Biblioteca Digital da Produção Intelectual - BDPI, Universidade de São Paulo
Biblioteca Digital da Produção Intelectual - BDPI
Departamento de Cirurgia - FM/MCG Artigos e Materiais de Revistas Científicas - FM/MCG
RESEARCH ARTICLE Open Access
miR-21 may acts as an oncomir by targeting
RECK, a matrix metalloproteinase regulator,
in prostate cancer
Sabrina Thalita Reis1,2*, José Pontes-Junior1,2,3, Alberto Azoubel Antunes1,3, Marcos Francisco Dall’Oglio1,2,
Nelson Dip1, Carlo Camargo Passerotti1,3, Guilherme Ayres Rossini3, Denis Reis Morais1, Adriano Joao Nesrallah1,2,
Camila Piantino1, Miguel Srougi1,2 and Katia R. Leite1,2
Abstract
Background: Prognosis of prostate cancer (PCa) is based mainly in histological aspects together with PSA serum
levels that not always reflect the real aggressive potential of the neoplasia. The micro RNA (miRNA) mir-21 has been
shown to regulate invasiveness in cancer through translational repression of the Metaloproteinase (MMP) inhibitor
RECK. Our aim is to investigate the levels of expression of RECK and miR-21 in PCa comparing with classical
prognostic factors and disease outcome and also test if RECK is a target of miR-21 in in vitro study using PCa cell
line.
Materials and methods: To determine if RECK is a target of miR-21 in prostate cancer we performed an in vitro
assay with PCa cell line DU-145 transfected with pre-miR-21 and anti-miR-21. To determine miR-21 and RECK
expression levels in PCa samples we performed quantitative real-time polymerase chain reaction (qRT-PCR).
Results: The in vitro assays showed a decrease in expression levels of RECK after transfection with pre-miR-21, and
an increase of MMP9 that is regulated by RECK compared to PCa cells treated with anti-miR-21. We defined three
profiles to compare the prognostic factors. The first was characterized by miR-21 and RECK underexpression (N = 25)
the second was characterized by miR-21 overexpression and RECK underexpression (N = 12), and the third was
characterized by miR-21 underexpression and RECK overexpression (N = 16). From men who presented the second
profile (miR-21 overexpression and RECK underexpression) 91.7% were staged pT3. For the other two groups 48.0%,
and 46.7% of patients were staged pT3 (p = 0.025).
Conclusions: Our results demonstrate RECK as a target of miR-21. We believe that miR-21 may be important in PCa
progression through its regulation of RECK, a known regulator of tumor cell invasion.
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Background
Prostate cancer (PCa) is the most common cancer
affecting males and the second leading cause of death in
men in many countries, including Brazil. For 2011
903,500 new cases and 258,400 deaths are estimated
worldwide [1]. Tumor staging, Gleason score and Pros-
tatic specific antigen (PSA) serum levels are the most
important prognostic factors; however, even taken to-
gether they cannot perfectly predict which patients are
at risk for progression [2]. There is a variety of treatment
options that ranges from active surveillance to androgen
deprivation. Therefore, identification of molecular mar-
kers that could contribute to prediction of PCa behavior
has been an area of active research.
MicroRNAs (miRNAs) are a class of small noncoding
RNA that regulate the expression of target genes by pro-
moting translational repression or degradation of
mRNAs [3,4]. In recent years, abnormalities in miRNA
expression have been identified in the progression of
various cancers and consequently have been proposed as
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potential targets for anticancer therapies [5]. miRNAs
have been shown to function as both tumor suppressors
or oncogenes in various cancers [6,7]. Using high-
throughput profiling of miRNA expression, miR-21 was
identified as being strongly elevated in many tumors in-
cluding breast, colorectal, and hepatocellular carcinoma
[8-11]. However, our knowledge of the molecular
mechanisms underlying the function of miR-21 in cancer
generally, and prostate cancer specifically, is limited.
miR-21 regulates the expression of multiple mRNA
targets associated with tumor invasiveness and micro-
vascular proliferation. It has been shown that mir-21
regulates cell invasiveness by directly controlling the
MMP inhibitor RECK (Reversion-inducing cysteine-rich
protein with Kazal motifs), a key inhibitor of several
MMPs. Indeed, RECK expression levels are predictive in
determining prognoses in a number of common cancers;
low levels of RECK are often associated with increased
invasiveness and poor prognosis [12,13]. Additionally, it
has been shown that inhibition of miR-21 results in
reduced MMP activity leading to reduction of cell motil-
ity and invasiveness, through increased expression of
RECK [14].
In this study, we will investigate if RECK is a target of
miR-21 in prostate cancer cell line DU-145 in in vitro
assays. Also we will evaluate the expression levels of
RECK, MMP9 controlled by RECK and miR-21 in PCa
tissue comparing with Gleason score, pathological stage,
pre-operatory PSA serum levels and the outcome of
patients with localized PCa treated with radical
prostatectomy.
Methods
Patients and tissue samples
The demographic and clinical characteristics of the 53
patients included in the study are exposed in Table 1.
After surgery, their PSA was measured every six months
for the first five years and then once annually after that.
Patients who underwent adjuvant or neoadjuvant treat-
ment were excluded from this study. All subjects pro-
vided informed consent for study participation and to
allow their biological samples to be analyzed genetically.
The study was approved by the Institutional Board of
Ethics (CAPPesq, Hospital das Clpinicas da Faculdade de
Medicina da Universidade de São Paulo, no. 0453/08).
We analyzed miR-21, RECK and MMP9 expression
levels in fresh-frozen tumor specimens randomly
selected from our tumor bank from patients with clinic-
ally localized PCa who underwent radical prostatectomy
by a single surgeon between 1993 and 2007 using quan-
titative real-time polymerase chain reaction (qRT-PCR)
using TaqMan primers. The control group consisted of
tissue specimens from 11 patients with benign prostatic
hyperplasia (BPH) who presented lower urinary tract
symptoms and underwent retropubic prostatic resection
(mean age 64±6.0 years).
We found three different profiles characterized as fol-
lows: [1] miR-21 and RECK underexpression (n = 25) [2]
miR-21 overexpression and RECK underexpression or
[3] miR-21 underexpression and RECK overexpression
(n = 16).
Then the three profile were correlated with Gleason
score, pathological stage (TNM 2010) and pre-operative
serum PSA levels (ng/mL). For this analysis, pathological
stage was defined as organ-confined (pT2) or non-
organ-confined (pT3). Gleason score was classified as
low grade (Gleason score ≤6) or high grade (Gleason
score ≥7). Preoperative PSA was divided as ≥10 ng/mL
or <10 ng/mL. Additionally, we analyzed miR-21 and
RECK expression levels and their relation to biochemical
recurrence, which was defined as PSA levels >0.4 ng/
mL, in a mean follow-up time of 66.2 months for all
patients.
RNA and miRNA isolation and cDNA synthesis
All tumor samples were obtained from surgical speci-
mens and immediately frozen at −170°C in liquid nitro-
gen. A section of the frozen fragment was stained with
hematoxylin and eosin to verify the presence of tumor in
at least 75% of the fragment in PCa patients and if there
was no tumor in control BPH patients. Total RNA was
isolated from tissue samples using a RNAaqueous Kit
(Applied Biosystems, CA, USA) and miRNA was isolated
with a mirVANA Kit (Applied Biosystems, CA, USA)
according to the manufacturer’s instructions. RNA and
miRNA concentration was determined by 260/280 nm
absorbance using a Nanodrop ND-1000 spectrophotom-
eter (Thermo Scientific).
cDNA from total RNA was generated using a High
Capacity cDNA Reverse Transcription Kit (Applied
Table 1 Demographic and clinical characteristics of 53
patients included in the study submitted to radical
prostatectomy to treat prostate cancer
Age (years) Mean 65.4
Min - Max 50 - 79
PSA (ng/ml) Mean 11.0
Min - Max 2.0 – 37.0
<10 n (%) 27 (50.1)
≥10 n (%) 26 (49.9)
Stage
pT2 n (%) 22 (42.3)
pT3 n (%) 30 (57.7)
Gleason Score
< 7 n (%) 22 (41.5)
≥ 7 n (%) 31 (58.5)
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Biosystems, CA, USA). Reactions were incubated at 25°
C for 10 min, followed by 37°C for 120 min and 85°C for
5 min. cDNA from miRNAs was generated using a Taq-
ManW miRNA Reverse Transcription kit (Applied Bio-
systems, Foster City, CA). Reactions were incubated at
16°C for 30 min, 42°C for 30 min and 85°C for 30 min.
All cDNAs were stored at −20°C until further use.
Quantitative real-time PCR of miR21, RECK and MMP9
Expression levels of the miR-21 and RECK were ana-
lyzed by qRT-PCR using the ABI 7500 Fast Real-Time
PCR System (Applied Biosystems). Target sequences
were amplified in a 10-μl reaction containing 5 μl of
TaqMan Universal PCR Master Mix, 0.5 μl of TaqMan
Gene Expression Assays for RECK and 0.5 μl of TaqMan
miRNA expression assays for miR-21, 1 μl of cDNA and
3.5 μl of DNase-free water. The PCR cycling conditions
were 2 minutes at 50°C, 10 minutes at 95°C and then 40
cycles of 15 seconds at 95°C and 1 min at 60°C. Betha-2
microglobulin was used as the endogenous control in
the analysis of RECK expression. RNU43 was used as
the endogenous control for miR-21 (Table 2).
We used the ΔΔCT method to calculate the relative
expression of the RECK and miR-21 using the formula
ΔΔCT= (CT target gene, PC sample - CT endogenous
control, PC sample) – (CT target gene, BPH sample -
CT endogenous control, BPH sample). The fold change
in gene expression was calculated as 2-ΔΔCT.
Cell lines
Human prostate cancer DU145 was purchased from
ATCC (American Type Culture Collection, Manassas,
USA). The cell lines were cultured in McCoy's
medium supplemented with 20% (v/v) heat-inactivated
fetal bovine serum (Sigma, St.Louis, MO, USA) under
an atmosphere of 5% CO2 at 37°C. At the time of
confluence, adherent cells were subcultured after de-
tachment using trypsin/EDTA (0.25% trypsin- 1.0 mM
ethylenediaminetetraacetate).
Cell transfection
The transfection of Pre-miR-21 and its antagomir anti-
miR-21 via NeoFX was performed by following the man-
ufacturer’s manual. Briefly, 2.5 μl de Pre e anti – miR-21
was mixed with 50 μl OptiMEM, and 1.5 μl of NeoFX
was mixed with 50 μl OptiMEM. This dilutions were
mixture and then, were incubated at room temperature
for 10 min. Untreated cells and cells transfected by
scrambled microRNA precursor with no target were
negative controls in our work.
Quantification of miR-21 and RECK, MMP9 mRNA
expression in DU145 cells by quantitative real time PCR
Twenty-four hours post transfection, the cells were
washed with 1xPBS and then RNA and miRNA were
extracted with mirVANA Kit (ambion), cDNA from total
RNA was generated using a High Capacity cDNA Re-
verse Transcription Kit (Applied Biosystems, CA, USA)
and from miRNAs was generated using a TaqManW
miRNA Reverse Transcription kit (Applied Biosystems,
Foster City, CA). The qRT-PCR amplification of cDNA
was performed using TaqMan MicroRNA assay for miR-
21, and TaqMan gene expression assay for RECK and
MMP-9.
Statistical analysis
Qualitative variables were expressed as numbers and
percentages. To compare the clinical characteristics of
patients with PCa, we used the Mann–Whitney or T
Student, Chi-squared and Fisher exact tests. Statistical
analysis was performed using SPSS 15.0 for Windows
using a significance of p ≤0.05.
Results
Analysis of 53 patients with PCa showed that miR-21
was overexpressed in 42.8% (median 1.64) and RECK in
57.2% (median 2.2) of malignant prostatic tissue sam-
ples, relative to control BPH samples (Figure 1.A). miR-
21 and RECK expression data and their correlation with
prognostic parameters are presented in Table 3. Since
RECK is a target of miR-21, we defined three profiles for
analysis. The first profile contained samples in which
miR-21 and RECK were underexpressed, 25 cases
(47.1%). The second profile was composed of samples in
which miR-21 was overexpressed and RECK underex-
pressed, 12 cases (22.6%), and the third profile was com-
posed of samples in which miR-21 was underexpressed
and RECK overexpressed, 16 cases (30.2%). Comparing
the pathological stage between the three groups we
observed that that 91.7% of patients were staged pT3
when miR-21 was overexpressed and RECK underex-
pressed. On the contrary, when miR-21 was underex-
pressed and RECK overexpressed only 46.7% of patients
were staged pT3, and when both were underexpressed
only 48.0% of patients were staged pT3 (p = 0.025)
(Table 4).
Additionally, there was a marginal statistical difference
between the three profiles when we examined
Table 2 Primers utilized
Gene symbol Assays ID
Mir21 002438
RNU43 001095
RECK Hs01019179_m1
MMP9 Hs00957562_m1
B2M Hs99999907_m1
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biochemical recurrence. From patients presenting miR-
21 overexpression and RECK underexpression, 63.6%
had biochemical recurrence compared with 50.0% and
25.0% of patients in the others profiles (p = 0.087)
(Table 4).There were no differences in the three groups
considering Gleason score or PSA pre-operatory serum
levels.
The expression level of MMP9 having as a control
BPH tissue was 5.32 times when miR21 was overex-
pressed and RECK underexpressed, and 5.48 times when
both miR21 and RECK were underexpressed. When
miR21 was underexpressed and RECK overexpressed
MMP9 was 3.1 times.
The in vitro assays after 24 h of DU145 exposition to
pre-miR21 and anti-miR-21, showed a 20 times increase
in miR21 expression, confirming the success of transfec-
tion (Figure 1.B). The supposed target gene RECK
showed two times reduction in expression when exposed
to pre-miR-21. Also, MMP9, regulated by RECK had
doubled its expression levels after exposition to pre-
miR21 (Figure 1.C).
Discussion
To understand the role of any miRNA in disease such as
cancer, the mRNA targets of that miRNA must be iden-
tified. Each miRNA has hundreds of targets and each
Figure 1 (A) Graphical representation of the expression levels of miR-21 and RECK in 27 patients with PCa compared with BPH which
included in two profiles: miR-21 overexpressed - RECK underexpressed, and miR-21 underexpressed - RECK overexpressed. (B) Graphical
representation of the expression levels of miR-21 in PCa cell treated with pre-miR-21 e anti-miR-21. (C) Graphical representation of the expression
levels of RECK and MMP9 in PCa cell treated with pre-miR-21 e anti-miR-21. Fold change in expression was calculated using the 2-ΔΔCT method.
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mRNA is target for different miRNAs. miR-21 plays a
role in the regulation of cell proliferation, apoptosis and
tumor invasiveness by targeting PTEN, PDCD4, and
RECK [15], and has been shown to be involved in gli-
omas carcinogenesis process. This is the first study to
explore the role of miR-21 controlling RECK in PCa cell
lines and PCa specimens. In PCa cell line DU-145 miR-
21 showed that directly inhibits RECK, a tumor
suppressor gene that is involved in the control of
MMP9. Studying 53 PCa patient samples, 22.6% exhib-
ited miR-21 overexpression and RECK underexpression
associated with non-organ confined tumors (pT3). We
therefore believe that miR-21 may be playing a role in a
subset of prostate cancers through regulation of RECK
expression levels.
The same phenomenon has been observed in other
types of human cancers. Liu et al. showed that inhibition
of miR-21 lead to a decrease in invasiveness in hepatocel-
lular carcinoma [15]. Inhibition of miR-21 leads to increas-
ing levels of RECK, a membrane-anchored glycoprotein
that inhibits tumor cell invasion by regulating MMP-2,
MMP-9 and MT1-MMP [16]. In tumors in which RECK
is absent or diminished, MMPs will be highly active, facili-
tating tumor promotion and progression. In our study, we
showed in PCa cell line transfected with pre-miR-21, a
decreased in the levels of RECK mRNA and consequently
an increased in the level of MMP9.
Recently, Zhang et al. have described the similar
results in gastric cancer [17]. Cancers which overex-
pressed miR-21 and had Helicobacter pylori infection
had a higher capacity for invasion and migration of
tumor cells. Here, we have demonstrated a similar asso-
ciation in PCa where 91.7% of tumors presenting overex-
pression of miR-21 were staged pT3.
The miR-21 is one of the most commonly implicated
miRNAs in cancer. Its expression is highly upregulated
in a variety of solid tumors including gliomas, breast,
lung and pancreas carcinomas [18,19]. Elevated miR-21
expression has been causally linked to increase in cell
proliferation, reduction in apoptosis, and migration of
several cancer cell lines [20]. However, the molecular
mechanisms mediating miR-21 function in cancer
Table 3 miR-21 and RECK expression data in the
malignant prostatic tissue according to Gleason score,
Pathological stage, PSA value and Biochemical
Recurrence
miR-21 RECK
Gleason Score
< 7 (n = 22) 0.63 0.88
≥ 7 (n = 31) 0.81 2.10
p-value 0.545 0.214
Pathological Stage
pT2 (n = 22) 0,36 1.18
pT3 (n = 30) 1,01 1.85
p-value 0.009 0.470
PSA value
<10 (n = 27) 0.68 0.94
≥10 (n = 26) 0.80 2.18
p-value 0.701 0.390
Biochemical Recurrence
W/n (n = 27) 0.52 1.05
With (n = 20) 1.12 2.61
p-value 0.051 0.366
Fold change in gene expression was calculated using the ΔΔCT method
(QRel = 2-ΔΔCT).
Table 4 Relative expression of miR-21 and RECK in the malignant prostatic tissue in three profiles
#miR-21 and#RECK "miR-21 and#RECK #miR-21 and"RECK P value
Gleason Score
< 7 56.0% 33.3% 31.3% 0.215
≥ 7 44.0% 67.7% 68.7%
Pathological Stage
pT2 52.0% 8.3% 53.3% 0.025
pT3 48.0% 91.7% 46.7%
PSA value
<10 60.0% 50.0% 37.5% 0.371
≥10 40.0% 50.0% 62.5%
Biochemical Recurrence
No 75.0% 36.4% 50.0% 0.087
Yes 25.0% 63.6% 50.0%
miR-21 and RECK underexpressed, miR-21 overexpressed and RECK underexpressed, and miR-21 underexpressed and RECK overexpressed, correlated either with
Gleason score, pathological stage, PSA serum value or biochemical recurrence. Fold change in gene expression was calculated using the ΔΔCT method (QRel = 2-
ΔΔCT).
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generally, and PCa specifically, are poorly understood.
MiR-21 regulates RECK, which we have observed can
function as a tumor suppressor gene in PCa (unpub-
lished data). RECK decreases the amount of active
MMP-2 and MMP-9 in conditioned medium and inhi-
bits metastatic activity in vitro [21] and in vivo [22]
through modulation of these MMPs, which are known
to be involved in cancer progression [23].
Our data show a tendency in association between
miR-21 overexpression and biochemical recurrence.
When miR-21 was overexpressed and RECK was under-
expressed 63.4% of patients suffered recurrence with
a mean follow up of 60 months (p= 0.087). We may
hypothesize that this specific profile is unfavorable for
prostate adenocarcinoma, and a higher number of patients
should be studied to confirm this preliminary finding.
In this first study we identify a possible role of miR-21
in the behavior of prostate cancer promoting a decay in
the levels of RECK mRNA allowing the overexpression
of MMP9. Interesting would be to prove also the decay
in protein levels using westerbloting, and this is a theme
of our next study.
Conclusions
In conclusion, we believe that miR-21 may be important
in PCa progression through its regulation of RECK, a
known regulator of tumor cell invasion. Experimental
studies must be performed in order to show the precise
role of miR-21 and MMP and its regulators, specially
RECK in prostate carcinogenesis. Consequently, sup-
pression of miR-21 would be considered as a potential
therapeutic tool in the treatment of the neoplasia.
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